I C U Medical Inc ICUI

$159.38 +2.20 (1.40%)

Valuation

Market cap
3,983,542,000
Revenue TTM
$2,231,260,000
Net income TTM
$730,000
PE ratio
23.46
Forward PE
21.76
Profit margin
0.03%
Debt to equity
0.57

Trading

Volume
227,600
Avg volume
285,226
Day's range
$157.15 – $161.32
Shares out
24,994,000
Stochastic %K
29%
Beta
0.86
Analysts
Strong Sell
Price target
$195.57

Price

Company profile

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardou...

Show more

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Industry
Medical Instruments & Supplies
Sector
Healthcare
Phone
949 366 2183
Website
https://www.icumed.com
Address
951 Calle Amanecer, San Clemente, United States

Latest news

Stocktwits

Trendrebel Sep 1, 10:38 AM
$ICUI Filled the gap. Now we´ll see how strong it really is around the two support-lines
0 replies
Estimize Aug 24, 1:03 PM
Wall St is expecting 2.14 EPS for $ICUI Q3 [Reporting 11/09 AMC] http://www.estimize.com/intro/icui?chart=historical&metric_name=eps&utm_co
0 replies
Trendrebel Aug 15, 9:41 AM
$ICUI I would like to play this gap fill. Not a lot of percentages, but still free money.
0 replies
Noname2022 Aug 13, 12:41 PM
$CRMD $ICUI Study with Clearguard HD caps & Defencath results later this year!
0 replies
EarningsInsider Aug 6, 9:32 PM
https://www.marketbeat.com/earnings/reports/2026-8-6-icu-medical-inc-stock/ $ICUI ICU Medical Earnings Transcript
0 replies
StocktwitsEarnings Aug 6, 8:18 PM
$ICUI Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.76 down -46.85% YoY • Reported revenue of $551.68M up 0.51% YoY • For Fiscal Year 2026, ICU Medical, Inc. is updating its estimates of GAAP net income to a range of $73 million to $83 million and Adjusted EBITDA to $415 million to $435 million.
0 replies
Estimize Aug 6, 3:01 PM
$ICUI reports after the close, Estimize Consensus +0.10 EPS and +2.33M Revs compared to WS http://www.estimize.com/icui/fq2-2026?utm_conten
0 replies
Noname2022 Aug 2, 1:06 PM
$CRMD $ICUI $DVA $FMS Clearguard HD: guessing DVA contract & best guess at access trends based on their marketing data (Fresenius uses both Clearguard HD & Defencath!) On the Q2 2024 call, ICU Medical said it had: “recently signed a multi-year committed agreement with a leading U.S. operator of dialysis clinics” Management said the agreement would expand its evidence base and help attract other dialysis operators. https://stockanalysis.com/stocks/icui/transcripts/192237-q2-2024/
0 replies